Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (10) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Dalmane (1) ·
Doral (1) ·
Edronax (1) ·
Fetzima (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Ludiomil (1) ·
Marplan (1) ·
Mogadon (1) ·
Mycostatin, Nystop, Nyamyc, Bio-Statin (1) ·
Nardil (1) ·
Norpramin (1) ·
Onfi (1) ·
Parnate (1) ·
Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Savella (1) ·
Serax (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Tranxene (1) ·
Valdoxan (1) ·
Versed (1) ·
Vivactil (1) ·
Xanax (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) ·
'"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1)
uses:
None (40) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) ·
'"`UNIQ--vote-00000D13-QINU`"', '"`UNIQ--vote-00000D14-QINU`"', '"`UNIQ--vote-00000D15-QINU`"', '"`UNIQ--vote-00000D16-QINU`"' (1) ·
'"`UNIQ--vote-00001235-QINU`"', '"`UNIQ--vote-00001236-QINU`"', '"`UNIQ--vote-00001237-QINU`"', '"`UNIQ--vote-00001238-QINU`"' (1)
starting dose:
preparations:
None (40) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) ·
100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)
fda max:
routes:
onset:
None (39) ·
30-60 min (immediate-release); 1-2 h (extended-release) (1) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Days for dermatophyte clearance; nail clearance over months (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Symptom relief within days (1)
duration:
halflife:
None (39) ·
11-13 h (immediate-release); 11-16 h (extended-release) (1) ·
Not meaningfully described (not systemically absorbed)'"`UNIQ--ref-00000D17-QINU`"' (1) ·
Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
None (39) ·
80-90% oral (1) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
None (39) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe in pregnancy (no systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 44 results in range #1 to #44.